IL300920A - A pyrimidopyrimidinane compound and a pharmaceutical composition comprising it - Google Patents
A pyrimidopyrimidinane compound and a pharmaceutical composition comprising itInfo
- Publication number
- IL300920A IL300920A IL300920A IL30092023A IL300920A IL 300920 A IL300920 A IL 300920A IL 300920 A IL300920 A IL 300920A IL 30092023 A IL30092023 A IL 30092023A IL 300920 A IL300920 A IL 300920A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- compound
- benzamide
- pyrimidin
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200119100 | 2020-09-16 | ||
| PCT/KR2021/012616 WO2022060094A1 (ko) | 2020-09-16 | 2021-09-15 | 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300920A true IL300920A (en) | 2023-04-01 |
Family
ID=80777269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300920A IL300920A (en) | 2020-09-16 | 2021-09-15 | A pyrimidopyrimidinane compound and a pharmaceutical composition comprising it |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12590098B2 (https=) |
| EP (1) | EP4215533B1 (https=) |
| JP (1) | JP7824667B2 (https=) |
| KR (1) | KR102673031B1 (https=) |
| CN (1) | CN116137815B (https=) |
| AU (1) | AU2021344164A1 (https=) |
| BR (1) | BR112023004179A2 (https=) |
| CA (1) | CA3190461A1 (https=) |
| IL (1) | IL300920A (https=) |
| MX (1) | MX2023003087A (https=) |
| WO (1) | WO2022060094A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06001098A (es) * | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| BRPI0514738A (pt) | 2004-08-31 | 2008-06-24 | Hoffmann La Roche | derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos |
| UY29439A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| RU2007147917A (ru) * | 2005-06-10 | 2009-07-20 | Айрм Ллк (Bm) | Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| GB201315072D0 (en) | 2013-08-23 | 2013-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| KR102591947B1 (ko) * | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2021
- 2021-09-15 MX MX2023003087A patent/MX2023003087A/es unknown
- 2021-09-15 CA CA3190461A patent/CA3190461A1/en active Pending
- 2021-09-15 JP JP2023515773A patent/JP7824667B2/ja active Active
- 2021-09-15 EP EP21869716.7A patent/EP4215533B1/en active Active
- 2021-09-15 IL IL300920A patent/IL300920A/en unknown
- 2021-09-15 KR KR1020210123331A patent/KR102673031B1/ko active Active
- 2021-09-15 CN CN202180063334.1A patent/CN116137815B/zh active Active
- 2021-09-15 WO PCT/KR2021/012616 patent/WO2022060094A1/ko not_active Ceased
- 2021-09-15 US US18/245,395 patent/US12590098B2/en active Active
- 2021-09-15 BR BR112023004179A patent/BR112023004179A2/pt unknown
- 2021-09-15 AU AU2021344164A patent/AU2021344164A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215533B1 (en) | 2026-02-11 |
| CN116137815A (zh) | 2023-05-19 |
| BR112023004179A2 (pt) | 2023-04-11 |
| US20230348474A1 (en) | 2023-11-02 |
| JP7824667B2 (ja) | 2026-03-05 |
| KR20220036895A (ko) | 2022-03-23 |
| EP4215533A4 (en) | 2024-12-18 |
| WO2022060094A1 (ko) | 2022-03-24 |
| JP2023541052A (ja) | 2023-09-27 |
| CN116137815B (zh) | 2025-08-19 |
| KR102673031B1 (ko) | 2024-06-07 |
| CA3190461A1 (en) | 2022-03-24 |
| MX2023003087A (es) | 2023-04-14 |
| AU2021344164A9 (en) | 2024-03-21 |
| AU2021344164A1 (en) | 2023-05-04 |
| US12590098B2 (en) | 2026-03-31 |
| EP4215533A1 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115716840B (zh) | 一种具有kras突变蛋白抑制作用的杂环化合物及其药物组合和用途 | |
| US7897762B2 (en) | Kinase inhibitors useful for the treatment of proliferative diseases | |
| JP5948352B2 (ja) | 新規なスルホンアミノキノリン系ヘプシジン拮抗薬 | |
| US11932647B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| US20230103791A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| US20090226377A1 (en) | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | |
| TWI810520B (zh) | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 | |
| US20230139808A1 (en) | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer | |
| US11548900B2 (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| US20180036317A1 (en) | Method of treating conditions with kinase inhibitors | |
| IL300920A (en) | A pyrimidopyrimidinane compound and a pharmaceutical composition comprising it | |
| US10889560B2 (en) | 4-amino-2-pyrido-bicyclic pyrimidines and use thereof as topoisomerase II inhibitors | |
| TW202246259A (zh) | 吡唑醯胺衍生物 | |
| CA2140018A1 (en) | Pyrimidine compounds used in the therapy | |
| HK40095524A (zh) | 吡唑酰胺衍生物 | |
| JPH11140086A (ja) | ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤 | |
| WO2026023667A1 (ja) | フェニルピペラジン誘導体 | |
| WO2022166468A1 (zh) | Bruton's酪氨酸激酶抑制剂及其应用 | |
| CN111808080A (zh) | 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用 |